Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Oncology

• Publication date

  2016-12-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/jco.2009.27.15_suppl.8593PMID 27962286
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data

  2021cites this paper
• Immunotherapeutic Strategies for Multiple Myeloma

  2020cites this paper
• MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics

  2017cites this paper
• Chemotherapy-free treatment in patients with follicular lymphoma

  2015cites this paper
• Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?

  2014cites this paper
• Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma.

  2014cites this paper
• Antibodies in Cancer Treatment: Early Clinical Development

  2014cites this paper
• Novel targeted therapies for mantle cell lymphoma

  2012cites this paper
• Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies

  2012cites this paper
• The future role of monoclonal antibody therapy in childhood acute leukaemias

  2012cites this paper
• Correlation of CD74 expression with the Ki-67-labeling index and CD138 in multiple myeloma: a clinicopathological and immunohistochemical study

  2012cites this paper
• CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease

  2011cites this paper
• Active and passive immunotherapy for lymphoma: proving principles and improving results.

  2011cites this paper
• Active and Adoptive Immunotherapy in Indolent Lymphoproliferative Diseases

  2011cites this paper
• Enhanced expression of CD74 in gastrointestinal cancers and benign tissues.

  2011cites this paper
• FTY 720 increases CD 74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death

  2011cites this paper
• FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.

  2011cites this paper
• Combination anti-CD 74 ( milatuzumab ) and anti-CD 20 ( rituximab ) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma

  2011cites this paper
• Experimental approaches in the treatment of multiple myeloma

  2011cites this paper
• The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival

  2011cites this paper
• New Antibody Conjugates in Cancer Therapy

  2010cites this paper
• Investigational immunotherapeutics for B-cell malignancies.

  2010cites this paper
• Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.

  2008cites this paper